----

----

| (Mark One) |
|------------|
| þ     |   | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

| o |   | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|---|--------|------------------------------------------------------------------------------------------|

|   | WaferGen Bio-systems, Inc.                             |   |
|--------|--------------------------------------------------------|--------|
|   | (Exact Name of Registrant as Specified in its Charter) |   |

|   | Nevada                                                         |   | 90-0416683                        |   |
|--------|----------------------------------------------------------------|--------|-----------------------------------|--------|
|   | (State or other jurisdiction of incorporation or organization) |   | (IRS Employer Identification No.) |   |

|   | 7400 Paseo Padre Parkway, Fremont, CA    |   | 94555      |   |
|--------|------------------------------------------|--------|------------|--------|
|   | (Address of principal executive offices) |   | (Zip Code) |   |

|   | (510) 651-4450                                             |   |
|--------|------------------------------------------------------------|--------|
|   | (Registrant’s telephone number, including area code) |   |

| Title of each class: None |   |   | Name of each exchange on which registered: None |
|---------------------------|--------|--------|-------------------------------------------------|
|                      |   |   |                                            |

| Common stock, $0.001 par value per share |
|------------------------------------------|
| (Title of Class)                         |

| Large accelerated filer  ̈                                                        | Accelerated filer  ̈         |
|--------------------------------------------------------------------------------------------|---------------------------------------|
| Non-accelerated filer  ̈  (Do not check if a smaller reporting company) | Smaller reporting company þ |

----

----

----

----

|          |                                                                                           |   | Page   |
|---------------|------------------------------------------------------------------------------------------------|--------|--------|
|          | FORWARD LOOKING STATEMENTS                                                                     |   | 1      |   |
|          | PART III                                                                                       |   |   |   |
| ITEM 10.      | Directors, Executive Officers and Corporate Governance                                         |   | 2      |   |
| ITEM 11.      | Executive Compensation                                                                         |   | 6      |   |
| ITEM 12.      | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |   | 11     |   |
| ITEM 13.      | Certain Relationships and Related Transactions, and Director Independence                      |   | 13     |   |
| ITEM 14.      | Principal Accountant Fees and Services                                                         |   | 14     |   |
|          |                                                                                           |   |   |   |
|          | PART IV                                                                                        |   |   |   |
| ITEM 15.      | Exhibits and Financial Statement Schedules                                                     |   | 15     |   |
|          |                                                                                           |   |   |   |
| SIGNATURES    |                                                                                           |   | 19     |   |
|          |                                                                                           |   |   |   |
| EXHIBIT INDEX |                                                                                           |   | 20     |   |

----

Table of Contents

----

Table of Contents

| Name                       |   | Age |   | Position                                                                                            |
|----------------------------|--------|-----|--------|-----------------------------------------------------------------------------------------------------|
| Alnoor Shivji              |   | 54  |   | Chief Executive Officer, President and Chairman of the Board                                        |
| Robert Coradini            |   | 51  |   | Director                                                                                            |
| Dr. Robert J. Hariri  |   | 52  |   | Director                                                                                            |
| Dr. R. Dean Hautamaki |   | 48  |   | Director                                                                                            |
| Makoto Kaneshiro           |   | 52  |   | Director                                                                                            |
| Joel Kanter                |   | 54  |   | Director                                                                                            |
| Dr. Timothy Triche    |   | 66  |   | Director                                                                                            |
| Mona Chadha                |   | 51  |   | Chief Operating Officer, Executive Vice President, Marketing and Business Development and Secretary |
| Donald Huffman             |   | 64  |   | Chief Financial Officer                                                                             |
| David Gelfand              |   | 66  |   | Chief Scientific Officer                                                                            |
| Janet Lankard              |   | 52  |   | Senior Vice President, Worldwide Sales and Support                                                  |

----

Table of Contents

----

Table of Contents

----

Table of Contents

| (1)    | honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;                                                 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                    |
| (2)    | full, fair, accurate, timely, and understandable disclosure in report and document that we file with, or submit to, the Security and Exchange Commission and in other public communications made by us; |
|   |                                                                                                                                                                                                    |
| (3)    | compliance with applicable government laws, rules and regulations;                                                                                                                                      |
|   |                                                                                                                                                                                                    |
| (4)    | the prompt internal reporting of violations of Code of Business Conduct and Ethics to an appropriate person or persons identified in the Code of Business Conduct and Ethics; and                       |
|   |                                                                                                                                                                                                    |
| (5)    | accountability for adherence to the Code of Business Conduct and Ethics.                                                                                                                                |

----

Table of Contents

|                                                                                                     |   |   |   |   |    |      |   |               |    | All Other |   |   |
|----------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|---------|-----------|--------|--------------------|---------|----------------|--------|--------|
|                                                                                                     |   | Fiscal |   | Salary |    | Bonus     |   | Option Awards |    | Compensation   |   | Total  |
| Name and Principal Position                                                                              |   | Year   |   | ($)    |    | ($)       |   | ($)                |    | ($)            |   | ($)    |
| Alnoor Shivji                                                                                            |   | 2010   |   | $      | 223,125 |      |   | $                  | — |           |   | $      | — |   |   | $ | — |   |   | $ | 223,125 |   |
| Chairman, President and Chief Executive Officer                                                          |   | 2009   |   | $      | 223,125 |      |   | $                  | — |           |   | $      | — |   |   | $ | — |   |   | $ | 223,125 |   |
| Mona Chadha                                                                                              |   | 2010   |   | $      | 225,000 |  (1) |   | $                  | — |           |   | $      | — |   |   | $ | — |   |   | $ | 225,000 |   |
| Chief Operating Officer and Executive Vice President of Marketing and Business Development and Secretary |   | 2009   |   | $      | 212,609 |  (1) |   | $                  | — |           |   | $      | 102,783 |  (3) |   | $ | — |   |   | $ | 315,392 |   |
| Donald Huffman                                                                                           |   | 2010   |   | $      | 64,038  |  (2) |   | $                  | — |           |   | $      | 119,356 |  (3) |   | $ | — |   |   | $ | 183,394 |   |
| Chief Financial Officer                                                                                  |   | 2009   |   | $      | — |      |   | $                  | — |           |   | $      | — |   |   | $ | — |   |   | $ | — |   |

| (1)    | Such officer became a Section 16B officer on March 20, 2009, and an annual salary of $225,000 commenced on that date pursuant to such executive officer’s employment agreement with the Company.                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (2)    | Such officer became a Section 16B officer when his employment commenced on September 13, 2010, and an annual salary of $225,000 commenced on that date pursuant to such executive officer’s employment agreement with the Company.                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (3)    | Amounts in this column reflect the aggregate grant date fair value of stock awards granted in the fiscal year computed in accordance with FASB ASC Topic 718 (rather than the dollar amount recognized for financial statement purposes for the fiscal year), excluding the impact of estimated forfeitures related to service-based vesting conditions, as previously required. For more information, see Note 2, “Summary of Significant Accounting Policies--Stock-Based Compensation” and Note 7, “Stock Awards” to the Financial Statements contained in Item 8 in the Original Report. |

----

Table of Contents

|           |   | Number of       |    | Number of         |   |     |    |       |
|----------------|--------|----------------------|---------|------------------------|--------|----------|---------|------------|
|           |   | Securities           |    | Securities             |   |     |    |       |
|           |   | Underlying           |    | Underlying             |   | Option   |    |       |
|           |   | Unexercised          |    | Unexercised            |   | Exercise |    | Option     |
|           |   | Options              |    | Options                |   | Price    |    | Expiration |
| Name           |   | Exercisable (#) |    | Unexercisable (#) |   | ($)      |    | Date       |
| Alnoor Shivji  |   |                 | 149,305 |  (1)              |   |     | 17,361  |  (1)  |   | $ | 1.50 |   |   |   | 5/31/2017 |   |
|           |   |                 | 50,000  |  (2)              |   |     | 25,000  |  (2)  |   | $ | 1.95 |   |   |   | 4/17/2018 |   |
|           |   |                 | 42,188  |  (3)              |   |     | 32,812  |  (3)  |   | $ | 1.35 |   |   |   | 9/30/2015 |   |
|           |   |                 | 13,542  |  (4)              |   |     | 11,458  |  (4)  |   | $  | 1.00 |   |   |   | 10/24/2015 |   |
| Mona Chadha    |   |                 | 70,189  |  (5)              |   |     | — |       |   | $ | 0.15 |   |   |   | 7/1/2016 |   |
|           |   |                 | 10,417  |  (2)              |   |     | 14,583  |  (2)  |   | $ | 1.95 |   |   |   | 4/17/2018 |   |
|           |   |                 | 28,125  |  (3)              |   |     | 21,875  |  (3)  |   | $ | 1.35 |   |   |   | 9/30/2015 |   |
|           |   |                 | 5,417   |  (4)              |   |     | 4,583   |  (4)  |   | $ | 1.00 |   |   |   | 10/24/2015 |   |
|           |   |                 | 109,375 |  (6)              |   |     | 140,625 |  (6)  |   | $ | 1.10 |   |   |   | 3/20/2016 |   |
| Donald Huffman |   |                 | — |  (7)              |   |     | 200,000 |  (7)  |   | $ | 1.56 |   |   |   | 9/13/17 |   |

| (1)    | Option to purchase shares of our common stock at an exercise price of $1.50 per share granted on May 31, 2007, which option vests in equal monthly installments over four years and expires 10 years after the date of grant.                                                                                                                                                                                                                                   |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (2)    | Option to purchase shares of our common stock at an exercise price of $1.95 per share granted on April 17, 2008, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when the optionee completes each full month of continuous service thereafter, and expires 10 years after the date of grant.    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (3)    | Option to purchase shares of our common stock at an exercise price of $1.35 per share granted on September 30, 2008, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous services after the vesting start date, and with respect to an additional 1/48th of the shares when optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant.    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (4)    | Option to purchase shares of our common stock at an exercise price of $1.00 per share granted on October 24, 2008, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant.       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (5)    | Option to purchase shares of our common stock at an exercise price of $0.15 per share granted on July 1, 2006, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when the optionee completes each full month of continuous service thereafter, and expires 10 years after the date of grant.      |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (6)    | Option to purchase our common stock at an exercise price of $1.10 per share granted on March 20, 2009, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant.                   |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| (7)    | Option to purchase shares of our common stock at an exercise price of $1.56 per share granted on September 13, 2010, which option vests with respect to the first 25% of the shares when the optionee completes 12 months of continuous service after the vesting start date, and with respect to an additional 1/48th of the shares when the optionee completes each full month of continuous service thereafter, and expires 7 years after the date of grant. |

----

Table of Contents

----

Table of Contents

| (a)                                  |   | (b)          |   |   | (c)    |   |   | (d)          |   |   | (e)          |   |   | (f)            |    |   | (g)            |   |    | (h)    |   |
|--------------------------------------|--------|--------------|--------|--------|--------|--------|--------|--------------|--------|--------|--------------|--------|--------|----------------|---------|--------|----------------|--------|---------|--------|--------|
|                                 |   |         |   |   |   |   |   |         |   |   |         |   |   | Change in |    |   |           |   |    |   |   |
|                                 |   |         |   |   |   |   |   |         |   |   |         |   |   | Pension        |    |   |           |   |    |   |   |
|                                 |   | Fees         |   |   |   |   |   |         |   |   |         |   |   | Value and |    |   |           |   |    |   |   |
|                                 |   | Earned       |   |   |   |   |   |         |   |   | Non-Equity   |   |   | Nonqualified   |    |   |           |   |    |   |   |
|                                 |   | or Paid |   |   |   |   |   |         |   |   | Incentive    |   |   | Deferred       |    |   |           |   |    |   |   |
|                                 |   | In           |   |   | Stock  |   |   | Option       |   |   | Plan         |   |   | Compensation   |    |   | All Other |   |    |   |   |
|                                 |   | Cash         |   |   | Awards |   |   | Awards       |   |   | Compensation |   |   | Earnings       |    |   | Compensation   |   |    | Total  |   |
| Name                                 |   | ($)          |   |   | ($)    |   |   | ($) (1) |   |   | ($)          |   |   | ($)            |    |   | ($)            |   |    | ($)    |   |
| Makoto Kaneshiro                     |   | $            | 15,000 |   |   | $      | 15,300 |         |   | $      | 11,674       |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 41,974 |   |
| Dr. R. Dean Hautamaki |   | $            | 30,000 |   |   | $      | 15,300 |         |   | $      | 11,674       |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 56,974 |   |
| Joel Kanter                          |   | $            | 45,000 |   |   | $      | 15,300 |         |   | $      | 11,674       |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 71,974 |   |
| Dr. Robert Hariri          |   | $            | 15,000 |   |   | $      | 15,300 |         |   | $      | 11,674       |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 41,974 |   |
| Robert Coradini                      |   | $            | 15,000 |   |   | $      | 15,300 |         |   | $      | 11,674       |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 41,974 |   |
| Nadine C. Smith(2)                   |   | $            | 15,000 |   |   | $      | 15,300 |         |   | $      | 11,674       |   |   | $              | — |   |           | $      | — |   |   | $ | — |   |   | $ | 41,974 |   |

| (1)    | The amounts shown in column (d) represent the aggregate grant date fair value of stock awards granted in 2010 computed in accordance with FASB ASC Topic 718. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                          |
| (2)    | Ms. Smith resigned from the Board of Directors in February 2011.                                                                                    |

|   | • | Retainers.  Each non-employee director shall receive an annual cash retainer fee of $15,000. The chairperson of the Audit Committee, the Compensation Committee and the Clinical Development Committee shall each receive an additional annual cash retainer fee of $15,000; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | • | Annual Equity Grants.  Each non-employee director shall receive annually (i) a stock option to purchase 20,000 shares of Common Stock, with 25% of the shares subject to the stock option vesting every three months, such that 100% of the shares subject to the option shall be fully vested on the one year anniversary of the date of grant (“Director Options”); and (ii) 10,000 restricted stock units, with 50% of the restricted stock units vested on the date of grant and the remaining 50% of the restricted stock units vesting every three months after the date of grant, such that 100% of the restricted stock units shall be fully vested on the one year anniversary of the date of grant (“Director RSUs”). For 2010, the Director Options and Director RSUs will be granted on the date of the Annual Meeting of Stockholders. Beginning in 2011, the Director Options and Director RSUs will be granted on the first trading day in January of each year.  |

----

Table of Contents

----

Table of Contents

Item 12. 

|                                                       |   |               |      |                        |   | Number of       |   |
|------------------------------------------------------------|--------|--------------------|-----------|-----------------------------|--------|----------------------|--------|
|                                                       |   |               |      |                        |   | Securities           |   |
|                                                       |   |               |      |                        |   | Remaining            |   |
|                                                       |   | Number of     |      |                        |   | Available for   |   |
|                                                       |   | Securities to |      |                        |   | Future Issuance |   |
|                                                       |   | Be                 |      |                        |   | Under Equity    |   |
|                                                       |   | Issued upon   |      |                        |   | Compensation         |   |
|                                                       |   | Exercise of   |      | Weighted-Average            |   | Plans                |   |
|                                                       |   | Outstanding        |      | Exercise Price of |   | (Excluding           |   |
|                                                       |   | Options,           |      | Outstanding                 |   | Securities           |   |
|                                                       |   | Warrants and  |      | Options, Warrants      |   | Reflected in    |   |
|                                                       |   | Rights             |      | and Rights             |   | Column (a))     |   |
| Plan Category                                              |   | (a)                |      | (b)                         |   | (c)                  |   |
| Equity compensation plans approved by security holders     |   |               | 5,543,893 |                        | $      | 1.52                 |   | $ | 2,191,821 |   |
| Equity compensation plans not approved by security holders |   |               | —   |                        |   | —              |   |   | — |   |
| Total                                                      |   |               | 5,543,893 |                        | $      | 1.52                 |   | $ | 2,191,821 |   |

|                                                    |   | Number of |      |         |   |
|---------------------------------------------------------|--------|----------------|-----------|--------------|--------|
|                                                    |   | Shares         |      | Percentage   |   |
|                                                    |   | Beneficially   |      | Beneficially |   |
| Name of Beneficial Owner                                |   | Owned          |      | Owned (1)    |   |
| 5% Holders:                                             |   |           |      |         |   |   |   |
| The Shivji Family Trust dated June 12, 2000        |   |           | 3,245,307 |  (2)    |   | 7.73 | % |
| William L. Collins                                      |   |           | 2,764,463 |  (3)    |   | 6.52 | % |
| Mark Tompkins                                           |   |           | 2,329,288 |  (4)    |   | 5.59 | % |
| Directors and Executive Officers:                       |   |           |      |         |   |   |   |
| Alnoor Shivji                                           |   |           | 6,509,565 |  (5)    |   | 15.27 | % |
| Dr. R. Dean Hautamaki                              |   |           | 648,861   |  (6)    |   | 1.55 | % |
| Robert Coradini                                         |   |           | 455,599   |  (7)    |   | 1.10 | % |
| Mona Chadha                                             |   |           | 270,606   |  (8)    |   | * |   |
| Dr. Robert Hariri                                  |   |           | 268,708   |  (9)    |   | * |   |
| Joel Kanter                                             |   |           | 202,500   |  (10)   |   | * |   |
| Makoto Kaneshiro                                        |   |           | 105,000   |  (11)   |   | * |   |
| Dr. Timothy Triche                                 |   |           | 12,000    |  (12)   |   | * |   |
| Donald Huffman                                          |   |           | —   |  (13)   |   | * |   |
| Directors and Executive Officers as a Group (9 persons) |   |           | 8,472,839 |         |   | 19.35 | % |

| * | Less than 1% |
|---|--------------|

| (1)    | Based on 41,350,201 shares of our common stock issued and outstanding as of April 27, 2011, which excludes 81,250 shares of unvested restricted stock.                                                                                                                                                                                                       |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                              |
| (2)    | Includes 631,755 shares of common stock issuable upon the exercise of currently exercisable warrants. Alnoor Shivji and his wife, Mariam Shivji, are the co-trustees of The Shivji Family Trust dated June 12, 2000 (“The Shivji Family Trust”). Its address is 692 Hillcrest Terrace, Fremont, CA 94539. See also footnote (5) in this section. |

----

Table of Contents

| (3)    | Includes 1,600,000 shares held by William L. Collins 2009 GRAT, 7,736 shares held by affiliates of Brencourt Advisors, LLC, 539,326 shares of common stock issuable upon the exercise of currently exercisable warrants held by William L. Collins 2009 GRAT and 542,519 shares of common stock issuable upon the exercise of currently exercisable warrants held by affiliates of Brencourt Advisors, LLC. William L. Collins has voting control and investment power over, but disclaims beneficial ownership of, the securities managed owned by William L. Collins 2009 GRAT. William L. Collins is the CEO and Managing Member of Brencourt Advisors, LLC, but lacks sole voting control and investment power over and disclaims beneficial ownership of the securities managed by Brencourt Advisors, LLC. Brencourt Advisors, LLC’s and William L. Collins’s address is 600 Lexington Avenue, 8th Floor, New York, NY 10022.                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (4)    | Includes 320,662 shares of common stock issuable upon the exercise of currently exercisable warrants. His address is c/o Gottbetter & Partners, 488 Madison Ave, 12th Floor, New York, NY 10022.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (5)    | Consists of (i) 2,483,952 shares of common stock, (ii) 314,064 shares of common stock issuable upon the exercise of currently exercisable warrants, (iii) 292,707 shares of common stock issuable upon the exercise of options that are exercisable within 60 days, (iv) 2,613,552 shares of common stock held by The Shivji Family Trust, (v) 631,755 shares of common stock issuable upon the exercise of currently exercisable warrants held by The Shivji Family Trust, (vi) 48,333 shares of common stock held by each of the Shivji Children’s Trust fbo Zahra Shivji, the Shivji Children’s Trust fbo Suraya Shivji and the Jameel Shivji Irrevocable Trust (the “Shivji Children’s Trusts”), and (vii) 9,512 shares of common stock issuable upon the exercise of currently exercisable warrants held by each of the three Shivji Children’s Trusts. Mr. Shivji and his wife, Mariam Shivji, are the co-trustees of The Shivji Family Trust and each of the three Shivji Children’s Trusts (together, the “Shivji Trusts”). Mr. Shivji disclaims beneficial ownership of the securities held by each of the Shivji Trusts, except to the extent he has a pecuniary interest therein. Excludes options to purchase 48,959 shares of common stock that are not exercisable within 60 days. See also footnote (2) in this section. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (6)    | Consists of (i) 1,250 shares of common stock, (i) 1,250 shares of restricted stock that will vest within 60 days, (iii) 345,625 shares of common stock issuable upon the exercise of options that are exercisable within 60 days, (iv) 226,883 shares of common stock held by Cojack Investment Opportunities, LLC (“Cojack”), and (v) 73,853 shares of common stock issuable upon the exercise of currently exercisable warrants held by Cojack. Excludes 6,250 shares of restricted stock that will not vest within 60 days and options to purchase 44,375 shares of common stock that are not exercisable within 60 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (7)    | Includes (i) 96,208 shares of common stock issuable upon the exercise of currently exercisable warrants, (ii) 1,250 shares of restricted stock that will vest within 60 days, and (iii) 60,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. Excludes 6,250 shares of restricted stock that will not vest within 60 days and options to purchase 20,000 shares of common stock that are not exercisable within 60 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (8)    | Consists of 270,606 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. Excludes options to purchase 134,583 shares of common stock that are not exercisable within 60 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (9)    | Includes (i) 53,708 shares of common stock issuable upon the exercise of currently exercisable warrants, (ii) 1,250 shares of restricted stock that will vest within 60 days, and (iii) 60,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. Excludes 6,250 shares of restricted stock that will not vest within 60 days and options to purchase 20,000 shares of common stock that are not exercisable within 60 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (10)   | Includes (i) 1,250 shares of restricted stock that will vest within 60 days, (ii) 90,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days, (ii) 75,000 shares of common stock held by the Kanter Family Foundation and (iii) 22,500 shares of common stock issuable upon exercise of currently exercisable warrants held by the Kanter Family Foundation. Joel Kanter and his brother, Joshua Kanter, have voting and dispositive power over all of the securities held by the Kanter Family Foundation. Mr. Kanter disclaims beneficial ownership of the securities held by the Kanter Family Foundation, except to the extent he has a pecuniary interest therein. Excludes 6,250 shares of restricted stock that will not vest within 60 days and options to purchase 20,000 shares of common stock that are not exercisable within 60 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

----

Table of Contents

| (11)   | Includes (i) 1,250 shares of restricted stock that will vest within 60 days, and (ii) 90,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. Excludes 6,250 shares of restricted stock that will not vest within 60 days and options to purchase 20,000 shares of common stock that are not exercisable within 60 days. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                      |
| (12)   | Consists of 12,000 shares of common stock issuable upon the exercise of options that are exercisable within 60 days. Excludes options to purchase 36,000 shares of common stock that are not exercisable within 60 days.                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                      |
| (13)   | Excludes options to purchase 200,000 shares of common stock that are not exercisable within 60 days.                                                                                                                                                                                                                                                                      |

----

Table of Contents

|               |   | 2010   |    |   | 2009   |   |
|--------------------|--------|--------|---------|--------|--------|--------|
| Audit fees         |   | $      | 171,415 |   |   | $      | 180,280 |   |
| Audit related fees |   |   | 44,357  |   |   |   | 81,214 |   |
| Tax fees           |   |   | 20,294  |   |   |   | 20,193 |   |
| All other fees     |   |   | — |   |   |   | — |   |
| Total Fees         |   | $      | 236,066 |   |   | $      | 281,687 |   |

----

Table of Contents

|   | • | should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------|

|   | • | were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|          |   |                                                                                                                                              |   |          |   | Incorporated by Reference |
|---------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|
| ExhibitNumber |   | Exhibit Description                                                                                                                               |   | FiledHerewith |   | Form                      |   | PeriodEnding |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 2.1           |   | Agreement and Plan of Merger and Reorganization, dated as of May 31, 2007, by and among WBSI, WaferGen Acquisition Corp., and WaferGen, Inc. |   |          |   | 8-K                       |   |   |   | 2.1 |   | 6/5/2007 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 2.2           |   | Certificate of Merger of WaferGen Acquisition Corp. with and into WaferGen, Inc., dated May 31, 2007                                         |   |          |   | 8-K                       |   |   |   | 2.2 |   | 1/16/2008 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.1           |   | Certificate of Incorporation of WBSI                                                                                                              |   |          |   | SB-2                      |   |   |   | 3.1 |   | 8/9/2006 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.2           |   | Certificate of Amendment to the Certificate of Incorporation of WBSI, dated January 31, 2007                                                 |   |          |   | 8-K                       |   |   |   | 3.1 |   | 2/1/2007 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 3.3           |   | Bylaws of WBSI                                                                                                                                    |   |          |   | SB-2                      |   |   |   | 3.2 |   | 8/9/2006 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 4.1           |   | Lockup Agreement dated January 14, 2008, among WBSI, Rodman & Renshaw LLC and R&R Biotech Partners LLC                               |   |          |   | SB-2/A                    |   |   |   | 4.1 |   | 1/16/2008 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 10.1 †  |   | Form of Warrants, made as of May 5, 2007, to purchase up to an aggregate of 115,424 shares of WBSI’s Common Stock                      |   |          |   | 10-K                      |   | 12/31/09 |   | 10.1 |   | 3/22/10 |
|          |   |                                                                                                                                              |   |          |   |                      |   |   |   |   |   |   |
| 10.2          |   | Form of Common Stock Purchase Warrant issued to investors in a private placement, the initial closing of which was held on May 31, 2007      |   |          |   | 8-K                       |   |   |   | 10.21 |   | 6/5/2007 |

----

Table of Contents

|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   | Incorporated by Reference |   |
|---------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|--------|
| ExhibitNumber |   | Exhibit Description                                                                                                                                                                                                                                                                                          |   | FiledHerewith |   | Form                      |   | PeriodEnding |   | Exhibit |   | Filing Date |   |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |   |
| 10.3          |   | Form of Warrant issued to Placement Agent in connection with a private placement, the initial closing of which was held on May 31, 2007                                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.22 |   | 6/5/2007 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.4 †  |   | Employment Agreement dated May 31, 2007, between WBSI and Alnoor Shivji                                                                                                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.26 |   | 6/5/2007 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.5          |   | Securities Purchase Agreement, dated May 19, 2008, by and among WaferGen Bio-systems, Inc. and the purchasers identified on the signature pages thereto                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.1 |   | 5/21/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.6          |   | Form of Common Stock Purchase Warrant issued to investors identified in the Securities Purchase Agreement dated May 19, 2008                                                                                                                                                                            |   |          |   | 8-K                       |   |   |   | 10.2 |   | 5/21/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.7 †  |   | WaferGen Bio-Systems, Inc. 2008 Stock Incentive Plan                                                                                                                                                                                                                                                         |   |          |   | 8-K                       |   |   |   | 10.1 |   | 7/3/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.8 †  |   | Form of Non-Qualified Stock Option award under 2008 Stock Incentive Plan                                                                                                                                                                                                                                     |   |          |   | 10-K                      |   | 12/31/2008 |   | 10.35 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.9          |   | Share Subscription Agreement and Shareholders’ Agreement dated May 8, 2008, by and among WaferGen Bio-systems, Inc., Malaysian Technology Development Corporation Sdn. Bhd. and WaferGen Biosystems (M) Sdn. Bhd.                                                                                 |   |          |   | 10-Q                      |   | 9/30/2008 |   | 10.1 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.10         |   | Put Agreement dated May 28, 2008, by and among WaferGen Bio-systems, Inc. and Holders of the Series A Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                     |   |          |   | 10-Q                      |   | 9/30/2008 |   | 10.2 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.11         |   | Put Option Agreement dated May 28, 2008, by and among Alnoor Shivji and Malaysian Technology Development Corporation Sdn. Bhd.                                                                                                                                                                          |   |          |   | 10-Q                      |   | 9/30/2008 |   | 10.3 |   | 11/14/2008 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.12 † |   | Letter Agreement dated January 16, 2009, by and between WBSI and Alnoor Shivji                                                                                                                                                                                                                          |   |          |   | 10-K                      |   | 12/31/2008 |   | 10.39 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.13         |   | Form of WBSI Distribution Agreement                                                                                                                                                                                                                                                                          |   |          |   | 10-K                      |   | 12/31/2008 |   | 10.42 |   | 3/27/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.14         |   | Share Subscription Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Prima Mahawangsa Sdn. Bhd. and Expedient Equity Ventures Sdn. Bhd.                                                                                                        |   |          |   | 8-K                       |   |   |   | 10.1 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.15         |   | Put Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc. and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                        |   |          |   | 8-K                       |   |   |   | 10.2 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.16         |   | Form of Put Option Agreement dated April 3, 2009, by and among Alnoor Shivji and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                      |   |          |   | 8-K                       |   |   |   | 10.3 |   | 4/14/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.17         |   | Deed of Adherence to the Share Subscription and Shareholders’ Agreement dated May 8, 2008, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Prima Mahawangsa Sdn. Bhd., Expedient Equity Ventures Sdn. Bhd. and Malaysian Technology Development Corporation Sdn. Bhd. |   |          |   | 10-Q                      |   | 3/31/2009 |   | 10.4 |   | 5/12/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.18         |   | Form of Subscription Agreement between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s 2009 private placement offering of units of securities                                                                                                             |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.5 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.19         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued June 16, 2009, to investors in the Company’s 2009 private placement offering of units of securities                                                                                                                    |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.6 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.20         |   | Registration Rights Agreement, dated June 16, 2009, between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s 2009 private placement offering of units of securities                                                                                   |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.7 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.21         |   | Form of Warrant to purchase shares of Common Stock of the Company, issued to Spencer Trask Ventures, Inc. and certain related parties in connection with the Company’s 2009 private placement offering of units of securities                                                                          |   |          |   | 10-Q                      |   | 6/30/2009 |   | 10.8 |   | 8/10/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.22 † |   | Employment Separation Agreement, dated June 17, 2009, by and among Amjad Huda and WaferGen Bio-systems, Inc.                                                                                                                                                                                            |   |          |   | 10-K                      |   | 12/31/09 |   | 10.22 |   | 3/22/10 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.23 † |   | Employment Separation Agreement, dated June 17, 2009, by and among Victor Joseph and WaferGen Bio-systems, Inc.                                                                                                                                                                                         |   |          |   | 10-K                      |   | 12/31/09 |   | 10.23 |   | 3/22/10 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |
| 10.24         |   | Share Subscription Agreement dated July 1, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd. and Kumpalan Modal Perdana Sdn. Bhd.                                                                                                                                        |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.1 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                         |   |          |   |                      |   |   |   |   |   |   |

----

Table of Contents

|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   | Incorporated by Reference |
|---------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|
| ExhibitNumber |   | Exhibit Description                                                                                                                                                                                                                                                                                                                                                                                                                    |   | FiledHerewith |   | Form                      |   | Period Ending |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.25         |   | Put Agreement dated July 1, 2009, by and among WaferGen Bio-systems, Inc. and Holders of Series B Redeemable Convertible Preference Shares in WaferGen Biosystems (M) Sdn. Bhd.                                                                                                                                                                                                                                                   |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.2 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.26         |   | Put Option Agreement dated July 1, 2009, by and among Alnoor Shivji and Kumpalan Modal Perdana Sdn. Bhd.                                                                                                                                                                                                                                                                                                                          |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.3 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.27         |   | Deed of Adherence dated July 1, 2009, to the Share Subscription and Shareholders’ Agreement dated May 8, 2008, and the Share Subscription Agreement dated April 3, 2009, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Prima Mahawangsa Sdn. Bhd., Expedient Equity Ventures Sdn. Bhd., Malaysian Technology Development Corporation Sdn. Bhd. and Kumpalan Modal Perdana Sdn. Bhd. |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.4 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.28 † |   | Employment Agreement, effective October 29, 2009, by and between the Company and Mona Chadha                                                                                                                                                                                                                                                                                                                                      |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.5 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.29         |   | Lease Agreement by and between WaferGen, Inc. and LBA Realty Fund III-Company VII, LLC dated October 22, 2009                                                                                                                                                                                                                                                                                                                     |   |          |   | 10-Q                      |   | 9/30/2009 |   | 10.6 |   | 11/13/2009 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.30         |   | Form of Subscription Agreement between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                                                   |   |          |   | S-1                       |   |   |   | 10.58 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.31         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued December 23, 2009, to investors in the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                                                      |   |          |   | S-1                       |   |   |   | 10.59 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.32         |   | Registration Rights Agreement, dated December 23, 2009, between WaferGen Bio-systems, Inc., and the investors party thereto in connection with the Company’s December 2009 and January 2010 private placement offering of units of securities                                                                                                                                                                     |   |          |   | S-1                       |   |   |   | 10.60 |   | 3/2/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.33         |   | Securities Purchase Agreement, dated July 1, 2010, between WaferGen Bio-systems, Inc. and each investor party thereto in connection with the Company’s July 2010 offering of units of securities                                                                                                                                                                                                                       |   |          |   | 8-K                       |   |   |   | 10.1 |   | 7/8/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.34         |   | Form of Warrants to purchase shares of Common Stock of the Company, issued July 7, 2010, to investors in the Company’s July 2010 offering of units of securities                                                                                                                                                                                                                                                       |   |          |   | 8-K                       |   |   |   | 4.1 |   | 7/8/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.35         |   | Form of Warrant to purchase shares of Common Stock of the Company, issued July 7, 2010, to placement agents and certain related parties in connection with the Company’s July 2010 offering of units of securities                                                                                                                                                                                                     |   |          |   | 10-Q                      |   | 6/30/2010 |   | 10.3 |   | 8/16/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.36 † |   | WaferGen Bio-Systems, Inc. 2008 Stock Incentive Plan, as amended                                                                                                                                                                                                                                                                                                                                                                       |   |          |   | 8-K                       |   |   |   | 10.1 |   | 9/22/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.37 † |   | Employment Agreement, effective September 3, 2010, by and between the Company and Donald Huffman                                                                                                                                                                                                                                                                                                                                  |   |          |   | 10-Q                      |   | 9/30/2010 |   | 10.2 |   | 11/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.38         |   | Loan and Security Agreement, dated December 7, 2010, between Oxford Finance Corporation, Wafergen Inc. and WaferGen Bio-systems, Inc.                                                                                                                                                                                                                                                                                             |   |          |   | 8-K                       |   |   |   | 10.1 |   | 12/13/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.39         |   | Warrant to purchase shares of Common Stock of the Company, issued December 7, 2010, to Oxford Finance Corporation                                                                                                                                                                                                                                                                                                                 |   |          |   | 8-K                       |   |   |   | 10.2 |   | 12/13/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.40         |   | Share Subscription Agreement dated December 14, 2010, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd. and Malaysian Technology Development Corporation Sdn. Bhd.                                                                                                                                                                                                                                       |   |          |   | 8-K                       |   |   |   | 10.1 |   | 12/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.41         |   | Put Agreement dated December 14, 2010, by and among WaferGen Bio-systems, Inc. and Malaysian Technology Development Corporation Sdn. Bhd.                                                                                                                                                                                                                                                                                         |   |          |   | 8-K                       |   |   |   | 10.2 |   | 12/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 10.42         |   | Amended and Restated Shareholders’ Agreement dated December 14, 2010, by and among WaferGen Bio-systems, Inc., WaferGen Biosystems (M) Sdn. Bhd., Malaysian Technology Development Corporation Sdn. Bhd. and Prima Mahawangsa Sdn. Bhd.                                                                                                                                                                                     |   |          |   | 8-K                       |   |   |   | 10.3 |   | 12/15/2010 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 21.1          |   | Subsidiaries of the Registrant                                                                                                                                                                                                                                                                                                                                                                                                         |   |          |   | 10-K                      |   | 12/31/10 |   | 21.1 |   | 3/31/11 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |
| 23.1          |   | Consent of Independent Registered Public Accounting Firm                                                                                                                                                                                                                                                                                                                                                                               |   |          |   | 10-K                      |   | 12/31/10 |   | 23.1 |   | 3/31/11 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                   |   |          |   |                      |   |   |   |   |   |   |

----

Table of Contents

|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |          |   | Incorporated by Reference |
|---------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|--------|---------------------------|
| ExhibitNumber |   | Exhibit Description                                                                                                                                                                                                                                                                                                                                                                                                                                                         |   | FiledHerewith |   | Form                      |   | Period Ending |   | Exhibit |   | Filing Date |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |          |   |                      |   |   |   |   |   |   |
| 31.1          |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer                                                                                                                                                                                                                                                                                                                                                                                                       |   |          |   | 10-K                      |   | 12/31/10 |   | 31.1 |   | 3/31/11 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |          |   |                      |   |   |   |   |   |   |
| 31.2          |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer                                                                                                                                                                                                                                                                                                                                                                                                       |   |          |   | 10-K                      |   | 12/31/10 |   | 31.2 |   | 3/31/11 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |          |   |                      |   |   |   |   |   |   |
| 31.3          |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer                                                                                                                                                                                                                                                                                                                                                                                                       |   | X             |   |                      |   |   |   |   |   |   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |          |   |                      |   |   |   |   |   |   |
| 31.4          |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer                                                                                                                                                                                                                                                                                                                                                                                                       |   | X             |   |                      |   |   |   |   |   |   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |          |   |                      |   |   |   |   |   |   |
| 32.1          |   | Section 1350 Certification of principal executive officer (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.) |   |          |   | 10-K                      |   | 12/31/10 |   | 32.1 |   | 3/31/11 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |   |          |   |                      |   |   |   |   |   |   |
| 32.2          |   | Section 1350 Certification of principal financial officer (This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.) |   |          |   | 10-K                      |   | 12/31/10 |   | 32.2 |   | 3/31/11 |

| † |   | Indicates a management contract or compensatory plan or arrangement. |
|---------|--------|----------------------------------------------------------------------|

----

Table of Contents

|                   |   | WAFERGEN BIO-SYSTEMS, INC.       |   |
|------------------------|--------|-------------------------------------------------|--------|
|                   | By:    | /s/  Alnoor Shivji                    |   |
| Date: May 2, 2011 |   | Alnoor Shivji                                   |   |
|                   |   | Chairman, President and Chief Executive Officer |   |

| SIGNATURE                         |   | TITLE                                                                                |   | DATE             |
|-----------------------------------|--------|--------------------------------------------------------------------------------------|--------|------------------|
|   /s/ ALNOOR SHIVJI     |   |                                                                                 |   |             |
| Alnoor Shivji           |   | Chairman, President andChief Executive Officer(principal executive officer)     |   | May 2, 2011 |
| /s/ DONALD HUFFMAN                |   |                                                                                 |   |             |
| Donald Huffman          |   | Chief Financial Officer(principal financial officer andprincipal accounting officer) |   | May 2, 2011 |
| /s/ ROBERT CORADINI               |   |                                                                                 |   |             |
| Robert Coradini         |   | Director                                                                             |   | May 2, 2011      |
| /s/ DR. ROBERT HARIRI             |   |                                                                                 |   |             |
| Dr. Robert Hariri       |   | Director                                                                             |   | May 2, 2011 |
| /s/ DR. R. DEAN HAUTAMAKI         |   |                                                                                 |   |             |
| Dr. R. Dean Hautamaki   |   | Director                                                                             |   | May 2, 2011 |
| /s/ JOEL KANTER                   |   |                                                                                 |   |             |
| Joel Kanter             |   | Director                                                                             |   | May 2, 2011 |
| /s/ MAKOTO KANESHIRO              |   |                                                                                 |   |             |
| Makoto Kaneshiro        |   | Director                                                                             |   | May 2, 2011 |
| /s/ DR. TIMOTHY TRICHE            |   |                                                                                 |   |             |
| Dr. Timothy Triche                |   | Director                                                                             |   | May 2, 2011 |

----

Table of Contents

| Exhibit No. |   | Description                                                           |
|-------------|--------|-----------------------------------------------------------------------|
|        |   |                                                                  |
| 31.3        |   | Rule 13a-14(a)/15d-14(a) Certification of principal executive officer |
|        |   |                                                                  |
| 31.4        |   | Rule 13a-14(a)/15d-14(a) Certification of principal financial officer |

----